References
- Gorski LA, Grothman L. Home infusion therapy. Semin Oncol Nurs 1996;12:193-201
- Dougherty L, Viner C, Young J. Establishing ambulatory chemotherapy at home. Prof Nurse (London, England) 1998;13:356-8
- Salman D, Barton S, Nabhani-Gebara S. Effect of environmental conditions on performance of elastomeric pumps. Am J Health-System Pharm AJHP Offic J Am Soc Health-System Pharm 2013;70,1100
- Chung IS, Cho HS, Kim JA, et al. The flow rate of the elastomeric balloon infusor is influenced by the internal pressure of the infusor. J Kor Med Sci 2001;16:702-6. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3054806&tool=pmcentrez&rendertype=abstract. [Last accessed 30 October 2014]
- Thiveaud D, Demazieres V, Lafont J. Comparison of the performance of four elastomeric devices. IndustryScience EJHP 2005;2:54-6
- Ackermann M, Maier S, Ing H, et al. Evaluation of the design and reliability of three elastomeric and one mechanical infusers. J Oncol Pharm Pract Offic Publ Int Soc Oncol Pharm Pract 2007;13,77-84. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17873107. [Last accessed 30 October 2014]
- Wang J, Moeller A, Ding YS. Effects of atmospheric pressure conditions on flow rate of an elastomeric infusion pump. Am J Health-System Pharm AJHP Offic J Am Soc Health-System Pharm 2012;69:587-91
- Hardy EM, Williamson C, Sewell GJ. An evaluation of six infusion devices for the continuous infusion of cytotoxic drugs in ambulatory patients. J Oncol Pharm Pract 1995;1:15-22
- Cassano-Piché A, White R, Jeon J, et al. Improving ambulatory chemotherapy safety: results and impact of a multi-disciplinary, multi-jurisdictional proactive risk study. In: Proceedings of the 2012 Symposium on Human Factors and Ergonomics in HealthCare. Human Factors and Ergonomics Society; 2012; pp. 52–9. Available at: http://www.researchgate.net/publication/268602668_Improving_Ambulatory_Chemotherapy_Safety_Results_and_Impact_of_a_Multi-Disciplinary_MultiJurisdictional_Proactive_Risk_Study. [Last accessed 7 January 2015]
- Anderson RT, Camacho FT, Balkrishnan R. Willing to wait?: the influence of patient wait time on satisfaction with primary care. BMC Health Serv Res 2007;7:31
- Dansky KH, Miles J. Patient satisfaction with ambulatory healthcare services: waiting time and filling time. Hosp Health Serv Admin 1997;42:165-77
- Michael M, Schaffer S, Egan P, et al. Improving wait times and patient satisfaction in primary care. J Healthcare Qual Offic Publ Natl Assoc Healthcare Qual 35:50-59-60. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23480405. [Last accessed 8 January 2015]
- Leddy KM, Kaldenberg DO, Becker BW. Timeliness in ambulatory care treatment. An examination of patient satisfaction and wait times in medical practices and outpatient test and treatment facilities. J Ambulat Care Manag 2003;26:138-49
- Mabro M, Artru P, André T, et al. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. Br J Cancer 2006;94:1287-92. Available at: http://dx.doi.org/10.1038/sj.bjc.6603095. [Last accessed 11 December 2014]
- Seesurn B. National survey on the use of elastomeric pumps in cancer patients in the United Kingdom. Kingston University; 2012. Available at: http://www.thesisabstracts.com/ThesisAbstract_518_National-Survey-On-The-Use-Of-Elastomeric-Pumps-In-Cancer-Patients-In-The-United-Kingdom.html
- Field K, Kosmider S, Jefford M, et al. Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice? J Oncol Prac Am Soc Clin Oncol 2008;4:271-6. Available at: http://jop.ascopubs.org/content/4/6/271.full. [Last accessed 7 January 2015]
- Wang G, Wan D, Zhou Z, et al. [Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis]. Ai zheng = Aizheng = Chin J Cancer 2007;26:411-14. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17430663. [Last accessed 7 January 2015]
- Seifert P, Baker LH, Reed ML, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975;36:123-8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1203840. [Last accessed 5 January 2015]
- Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nature Rev Cancer 2005;5:447-58
- Blaschke M, Cameron S, Emami K, et al. Measurement of 5-FU plasma levels in patients with advanced cancer: correct approach to practical procedures is essential. Int J Clin Pharmacol Ther 2011;49:83-5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21176739. [Last accessed 10 December 2014]
- Baxter clinician guide, Baxter elastomeric devices. Baxter Corporation; 2014. http://www.capca.ca/wp-content/uploads/Baxter-Elastomeric-Pumps-Clinician-Guide11.pdf
- Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol Offic J Am Soc Clin Oncol 2008;26:2099-105. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18445839. [Last accessed 11 December 2014]
- Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol Offic J Am Soc Clin Oncol 1998;16:1470-8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9552054. [Last accessed 9 January 2015]
- Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996;77:441-51. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8630950. [Last accessed 9 January 2015]
- Ychou M, Duffour J, Kramar A, et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemo Pharmacol 2003;52:282-90. http://www.ncbi.nlm.nih.gov/pubmed/12827293. [Last accessed 11 December 2014]
- Sewell G. The clinical impact of dose-banding. In Automation standardization for injectable preparation. Hyères; Hyéres. 2006. p. 1. Available at: http://www.gerpac.eu/spip.php?article289
- Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7877646. [Last accessed 8 January 2015]
- Plumridge RJ, Sewell GJ. Dose-banding of cytotoxic drugs: a new concept in cancer chemotherapy. Am J Health-System Pharm AJHP Offic J Am Soc Health-System Pharm 2001;58:1760-4
- Salman D, Gomes B, Paolo A, et al. Optimising ambulatory chemotherapy services: a system for monitoring drug delivery in elastomeric pumps. NCRI Cancer Conference; November 2015. Liverpool. Available at: http://abstracts.ncri.org.uk/abstract/optimising-ambulatory-chemotherapy-services-a-system-for-monitoring-drug-delivery-in-elastomeric-pumps-2/. [Last accessed 19 May 2017]